|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1994-8-17
|
|
pubmed:abstractText |
1. In this study the renal selectivity of dopamine and its prodrugs L-dopa and gludopa, with respect to their effects on regional blood flow, vascular resistance and central haemodynamics was investigated in normal rats and in rats with glycerol-induced acute renal failure (ARF). 2. In normal, anaesthetized rats, dopamine as well as its prodrugs caused a dose-dependent reduction of vascular resistance in the kidney (RR), mesentery (MR) and hindquarters (HQR) (dose range: dopamine: 0.1-5 mumol kg-1 h-1; L-dopa and gludopa: 1-200 mumol kg-1 h-1). Blood pressure and heart rate were affected at the highest dose only. 3. Administration of glycerol induced a preferential renal vasoconstriction; renal blood flow (-60%) and vascular resistance (+190%) were significantly more affected than MR (+40%) and HQR (+60%). This was only ameliorated by a low rate (10 mumol kg-1 h-1) infusion of gludopa: the glycerol-induced reduction of renal flow and increase in RR were significantly attenuated. A high dose of gludopa (100 mumol kg-1 h-1) or any dose of L-dopa or dopamine did not induce this beneficial effect. The glycerol-induced increase in MR and HQR was not attenuated by any of the treatments used. 4. The results indicate that gludopa is not renally selective at a pharmacodynamic level in normal, anaesthetized rats. Contrary to this, a low dose of gludopa does cause a renal selective vasodilatation and reduction of RR in rats with glycerol-induced ARF. This difference could be explained by a difference in renal vascular tone between normal rats and glycerol-induced ARF rats. A high dose ofgludopa does not cause these renal-selective effects: renal resistance and renal flow are at the same level as following glycerol and saline. This is probably due to the systemic effects of the released dopamine.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-1352429,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-14320300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-1521369,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-1675291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-1717786,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-1969473,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-1972967,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-1974290,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-2072293,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-2124159,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-2330978,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-2331567,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-2483441,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-2527048,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-2571302,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-2592568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-3123118,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-3129006,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-3277887,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-3946607,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-3973832,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-487520,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-6101340,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-6407799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-660553,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-6804154,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-6817778,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8032598-8428205
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0007-1188
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
111
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1117-22
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8032598-Acute Kidney Injury,
pubmed-meshheading:8032598-Animals,
pubmed-meshheading:8032598-Dihydroxyphenylalanine,
pubmed-meshheading:8032598-Dopamine,
pubmed-meshheading:8032598-Glycerol,
pubmed-meshheading:8032598-Hemodynamics,
pubmed-meshheading:8032598-Kidney,
pubmed-meshheading:8032598-Levodopa,
pubmed-meshheading:8032598-Male,
pubmed-meshheading:8032598-Rats,
pubmed-meshheading:8032598-Rats, Wistar,
pubmed-meshheading:8032598-Renal Circulation
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Regional haemodynamic effects of dopamine and its prodrugs L-dopa and gludopa in the rat and in the glycerol-treated rat as a model for acute renal failure.
|
|
pubmed:affiliation |
Department of Pharmacology, University of Limburg, Maastricht, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
